Igyxos S.A. has completed a Series A fundraising
Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.
Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.
Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.
Marie-Christine Maurel
CSO and Founder, Igyxos, S.A.
Talk to the deal team
Related deals
Main Capital Partners has acquired a majority stake in CarWise and AutoDisk
CarWise and AutoDisk (together “CarWise”), leading providers of integrated front-, mid- and back-office ERP software for the leasing and car rental sector in the Benelux, have sold a majority stake to Main Capital Partners (“Main”), a prominent European software investor.
Learn moreRAM Infotechnology has acquired Interoperability Group with support from Keensight Capital
RAM Infotechnology (RAM-IT) has acquired Interoperability Group, a leading Dutch provider of healthcare IT solutions, with the support of Keensight Capital, a leading European growth buy-out investor specializing in technology and healthcare.
Learn moreTages Capital SGR has acquired two RTB biomethane plants from Finpower Project
Tages Capital SGR, through its fund Tages Helios Net Zero, has acquired a portfolio consisting of two ready-to-build (RTB) biomethane plants located in Southern Italy.
Learn more